PMID- 15920055
OWN - NLM
STAT- MEDLINE
DCOM- 20050920
LR  - 20190516
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 28
IP  - 6
DP  - 2005 Jun
TI  - A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) 
      and risk of coronary heart disease among women with type 2 diabetes.
PG  - 1376-82
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha), a cytokine secreted by 
      adipose tissue and other cells, might play a role in insulin resistance. RESEARCH 
      DESIGN AND METHODS: Of 32,826 women from the Nurses' Health Study who provided 
      blood at baseline, we followed 929 women with type 2 diabetes. During 10 years of 
      follow-up, we documented 124 incident cases of coronary heart disease (CHD). 
      RESULTS: After adjustment for age, smoking, BMI, and other cardiovascular risk 
      factors, the relative risks (RRs) comparing extreme quartiles of soluble 
      TNF-alpha receptor II (sTNF-RII) were 2.48 (95% CI 1.08-5.69; P = 0.034) for 
      myocardial infarction (MI) and 2.02 (1.17-3.48; P = 0.003) for total CHD. The 
      probability of developing CHD over 10 years was higher among diabetic subjects 
      with substantially higher levels of both sTNF-RII (>75th percentile) and HbA(1c) 
      (>7%), compared with diabetic subjects with lower levels (25% vs. 7%, P < 
      0.0001). Diabetic subjects with only higher sTNF-RII or HbA(1c) had similar 
      (16-17%) risk. In a multivariate model, diabetic subjects with higher levels of 
      both sTNF-RII and HbA(1c) had an RR of 3.66 (1.85-7.22) for MI and 3.03 
      (1.82-5.05) for total CHD, compared with those with lower levels of both 
      biomarkers. CONCLUSIONS: Increased levels of sTNF-RII were strongly associated 
      with risk of CHD among diabetic women, independent of hyperglycemia.
FAU - Shai, Iris
AU  - Shai I
AD  - Department of Epidemiology, Harvard School of Public Health, 677 Huntington 
      Avenue, Boston, MA 02115, USA. ishai@hsph.harvard.edu
FAU - Schulze, Matthias B
AU  - Schulze MB
FAU - Manson, Joann E
AU  - Manson JE
FAU - Rexrode, Kathryn M
AU  - Rexrode KM
FAU - Stampfer, Meir J
AU  - Stampfer MJ
FAU - Mantzoros, Christos
AU  - Mantzoros C
FAU - Hu, Frank B
AU  - Hu FB
LA  - eng
GR  - CA 87969/CA/NCI NIH HHS/United States
GR  - DK 58845/DK/NIDDK NIH HHS/United States
GR  - HL 34594/HL/NHLBI NIH HHS/United States
GR  - HL 65582/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Coronary Disease/*epidemiology
MH  - Diabetes Mellitus, Type 2/*blood/physiopathology
MH  - Diabetic Angiopathies/*epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hyperglycemia/blood/epidemiology
MH  - Life Style
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor, Type II/*blood
MH  - Risk
MH  - Smoking
MH  - Time Factors
EDAT- 2005/05/28 09:00
MHDA- 2005/09/21 09:00
CRDT- 2005/05/28 09:00
PHST- 2005/05/28 09:00 [pubmed]
PHST- 2005/09/21 09:00 [medline]
PHST- 2005/05/28 09:00 [entrez]
AID - 28/6/1376 [pii]
AID - 10.2337/diacare.28.6.1376 [doi]
PST - ppublish
SO  - Diabetes Care. 2005 Jun;28(6):1376-82. doi: 10.2337/diacare.28.6.1376.